- Home
- News & Events
- In the News
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Strategic Commercialisation of Multi-Indication Obesity Therapies: Balancing Early Access, Pricing, and Lifecycle Value
A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline.
-
Survey of Obesity Developers Suggests Multi-Indication Approaches are Vital but Demanding
Following the rapid label expansion of drugs such as semaglutide and tirzepatide in recent years, drug developers have broadly adopted multi-indication strategies for obesity and related comorbidities. An ICON survey of 155 developers focused on these therapeutic areas reflects this growing trend.
-
Talking the talk
At ICON ensuring scientifically representative participation is not a stand-alone initiative, it’s embedded into every trial we support, shaping smarter, faster, higher-quality research. We start with the patient’s voice.
-
Plan, lead, deliver: A framework for regulatory writing success
This article in IBI highlights how strategic planning, leadership and coordination are critical to delivering high quality regulatory submissions with confidence and efficiency.
-
Flexibility is the differentiator in highly competitive RTSM space, says ICON
Read how ICON’s Alyssa Gilliam highlights that “system flexibility, ease of use, integration capabilities, and the ability to support increasingly complex clinical trial supply strategies” have become the defining differentiators in the fast‑evolving RTSM market.
-
Making early AD trials feasible
Early intervention in neurodegenerative diseases, such as Alzheimer’s, offers the potential to slow or prevent disease progression, and increase success rates for clinical development.
-
ICON named to TIME World's Most Sustainable Companies 2025 list
This list ranks the world’s 500 most sustainable companies based on their public commitment to and progress toward sustainability targets. ICON was one of nine Irish-based companies to make this global list, recognising the impact of our ICON Cares programme.
-
The Evolving Cost-Benefit Landscape of Biosimilar Drug Development
The patent cliff for biologic medicines presents an opportunity for developers of biosimilars, but historically there are challenges too. The landscape however is changing, supporting easier paths to market.
-
Regulatory Strategy, The Maestro
As part of Pharma Tech Outlook's Regulatory Strategy, The Maestro Q&A series, ICON answers a range of questions around regulatory in clinical trials, timing and other considerations.
-
NHS App to match patients with clinical trials under 10-year health plan
Dr Andrew Garrett, Executive VP Scientific Operations, ICON, comments on the UK government’s announcement on boost to clinical trials.